||ORD SHS NPV
||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Norwood Immunology Share Discussion Threads
Showing 1 to 9 of 25 messages
Chat Pages: 1
|I'm not actually a doctor
I'd imagine you're the latest name from one of my 'friends' on another thread. However....
In this case, its exploiting the body's own immune system to effect therapeutic benefits. But immunology is a wider field relating to the immune system in general.|
|As a doctor, would you please explain to me what immunology is?
|bump, fell off my list|
|There could be some subsequent interest in use of their virosomes to deliver RNAi...
: J Liposome Res. 2007;17(1):39-47. Links
Cellular delivery of siRNA mediated by fusion-active virosomes.Huckriede A, De Jonge J, Holtrop M, Wilschut J.
Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
RNA interference is expected to have considerable potential for the development of novel specific therapeutic strategies. However, successful application of RNA interference in vivo will depend on the availability of efficient delivery systems for the introduction of small-interfering RNA (siRNA) into the appropriate target cells. This paper focuses on the use of reconstituted viral envelopes ("virosomes"), derived from influenza virus, as a carrier system for cellular delivery of siRNA. Complexed to cationic lipid, siRNA molecules could be efficiently encapsulated in influenza virosomes. Delivery to cultured cells was assessed on the basis of flow cytometry analysis using fluorescently labeled siRNA. Virosome-encapsulated siRNA directed against Green Fluorescent Protein (GFP) inhibited GFP fluorescence in cells transfected with a plasmid encoding GFP or in cells constitutively expressing GFP. Delivery of siRNA was dependent on the low-pH-induced membrane fusion activity of the virosomal hemagglutinin, supporting the notion that virosomes introduce their encapsulated siRNA into the cell cytosol through fusion of the virosomal membrane with the limiting membrane of cellular endosomes, after internalization of the virosomes by receptor-mediated endocytosis. It is concluded that virosomes represent a promising carrier system for cellular delivery of siRNA in vitro as well as in vivo.
Norwood's virosome patents
Final rejection recieved in the US on 11 Nov 07
Examiner's issues to be resolved:
- can the patent be limited to 1-8 carbon atoms, when the original application was 1-12 - does this matter and why have they limited in this way (presumably explained in an earlier document that I've not read yet)
- substituting detergent for short-chain phospholipid could have been anticipated by Johnson et al and Hauser
Might be worth a punt when the patent issues are sorted out in 6 months time
& if they've sorted out further finances|
|Ah, they raised funds earlier!
A years' cash left for now.
Would be interesting to see if they have any catalysts that could bring in income over the next year?
Furthermore, if they have valued IP, they could be taken out?
(I dont hold this stock by the way)
"On 27 November 2006, the Group completed a #6.6m ($16.8m) fundraising before
expenses, with the issue and placement of 55,000,000 ordinary shares"|
|No fundraising yet... I was thinking of calling the company to ask what their plan is?|
|Not sure why these guys have been out acquiring other companies when they dont have much cash. May have been bargains, but I think a fundraising may be coming shortly?|
|I think someone should have told them "prevention better than the cure"|
|Over 10 million shares dumped. Anyone got any info?|
Chat Pages: 1